Beyond Air, Inc.
Beyond Air, Inc. functions as a specialized entity involved in both the development of medical devices and biopharmaceutical solutions. A central part of its operations is the LungFit platform, an innovative system that generates and delivers nitric oxide. Within this platform, LungFit PH is currently available, used to address persistent pulmonary hypertension in infants. Furthermore, the company is advancing LungFit PRO, a product intended for various viral lung ailments like community-acquired viral pneumonia (including COVID-19) and bronchiolitis in hospital settings. It is also creating LungFit GO, which aims to treat nontuberculous mycobacteria infections. The organization adopted its current name, Beyond Air, Inc., in June 2019, having previously been known as AIT Therapeutics, Inc. Its headquarters are situated in Garden City, New York.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q1 | -11.00 | $2M | -$5M |
| 2026 Q4 | -0.60 | $2M | -$5M |
| 2025 Q3 | -17.00 | $2M | -$4M |
| 2025 Q2 | -25.00 | $2M | -$5M |
| 2025 Q1 | -30.60 | $2M | -$5M |
| 2025 Q4 | -35.80 | $1M | -$8M |
| 2024 Q3 |
| -59.20 |
| $1M |
| -$8M |
| 2024 Q2 | -113.40 | $798,000 | -$15M |